CLEC9A and neoplasm: Bispecific forms of selicrelumab that specifically target DCs (via CD11c, DEC-205, or CLEC9A arms) have shown potent anti-tumor activity in preclinical models,114 suggesting that DC activation is not the cause of the observed dose-limiting toxicities.